OakChart

Rafael Holdings Inc

RFLReal Estate·Real Estate Services·USA·Micro·NYSE·Nov 12 • 10:42 AM ET

1.08-0.01 (-1.38%)
2026-11-12 17:13 CET
Market cap
56.88 USD m
Revenue, TTM
0.87 USD m
Net income, TTM
-29.64 USD m
Free cash flow, TTM
-30.00 USD m
EPS diluted, TTM
-0.58
P/E
-
Compare

Price

RFL against its 20, 50 and 200-day averages
2050200
Patternshover a marker to name it
smoothed
RS 01.002.003.004.001.1M2.3MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26RFLclose 1.0820-day 1.1650-day 1.60200-day 1.671.0852w high

72.9% under the 52-week high of 3.96 on 1 Jul 2026. 52-week low 0.99 on 6 Nov 2026. Last 15 sessions, 35.9% high to low. This session is unfinished.

Volume 0.15× normal · the line is the 50-bar volume average

Profile

RFL
52-week range, 3% of the way up
0.993.96

Rafael Holdings, Inc. owns an interest in clinical and early-stage pharmaceutical companies. It operates through the following segments: Healthcare, Infusion Technology, and Real Estate. The Healthcare segment relates to the activities of LipoMedix, Barer, Farber, and Rafael Medical Devices. The Infusion Technology segment manages equity interest on Day Three. The Real Estate segment refers to the company's real estate holdings. The company was founded in 2017 and is headquartered in Newark, NJ.

Employees17
IPOMar 27, 2018
Beta0.72
ATR, 14d0.12
Rel volume0.15
Short float0.83%
Insider own32.60%
Inst own7.40%

Snapshot

6 groups

Valuation

Index-
Market Cap56.11M
Enterprise Value40.31M
Income-29.64M
Sales0.87M
Book/sh1.27
Cash/sh0.42
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees17
IPOMar 27, 2018

Ratios

P/E-
Forward P/E-
PEG-
P/S64.49
P/B0.85
P/C2.54
P/FCF-
EV/EBITDA-
EV/Sales46.33
Quick Ratio2.32
Current Ratio2.35
Debt/Eq0.01
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.58
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y-16.25% 17.01%
Sales past 3/5Y46.32% 1.73%
EPS Y/Y TTM43.74%
Sales Y/Y TTM-4.69%
EPS Q/Q36.74%
Sales Q/Q-30.29%
Earnings-
EPS/Sales Surpr.- -

Ownership

Insider Own32.60%
Insider Trans0.00%
Inst Own7.40%
Inst Trans4.38%
ROA-30.06%
ROE-36.88%
ROIC-44.69%
Gross Margin71.85%
Oper. Margin-3821.17%
Profit Margin-3390.73%
SMA20-7.55%
SMA50-32.68%
SMA200-35.78%
Trades-

Technical

Shs Outstand51.39M
Shs Float35.17M
Short Float0.83%
Short Ratio2.06
Short Interest0.29M
52W High3.96 -72.85%
52W Low0.99 8.57%
Volatility10.42% 9.86%
ATR (14)0.12
RSI (14)34.45
Beta0.72
Rel Volume0.15
Avg Volume142.29K
Volume6,389

Performance

Perf Week1.42%
Perf Month-24.83%
Perf Quarter-45.98%
Perf Half Y-17.94%
Perf YTD-8.90%
Perf Year-15.35%
Perf 3Y-38.56%
Perf 5Y-84.17%
Perf 10Y-
Recom-
Target Price-
Prev Close1.09
Price1.08
Change %-1.38%

Peers

Mkt cap
TickerCompanyMkt cap
ZVRAZevra Therapeutics Inc679.54M
MAYSJ.W. Mays Inc90.16M
STHOStar Holdings94.23M
FBIOFortress Biotech Inc68.71M
CRDFCardiff Oncology Inc58.17M
RAREUltragenyx Pharmaceutical Inc1.69B
ABEOAbeona Therapeutics Inc129.44M
DNLIDenali Therapeutics Inc3.08B
PASGPassage Bio Inc12.13M
TSHATaysha Gene Therapies Inc1.38B

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 696.31B
VXFVanguard Extended Market Index ETFAUM: 30.79B
IWCiShares Micro-Cap ETFAUM: 1.23B
DFMCU.S. Micro Cap Portfolio ETF Class Shares-
DFASU.S. Small Cap Portfolio-ETF Class Shares-
DFACU.S. Core Equity 2 Portfolio-ETF Class Shares-
DXUVUS Vector Equity Portfolio ETF Class Shares-
DCORUS Core Equity 1 Portfolio ETF Class Shares-
DFUSDimensional U.S. Equity Market ETF-

News

latest 14 of 200
  • Rafael Holdings to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference (GlobeNewswire) +8.00%
  • Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Corporate Update (GlobeNewswire) -7.44%
  • Rafael Holdings Announces Submission of New Drug Application to FDA for Trappsol Cyclo (remibetadex) for the Treatment of Niemann-Pick Disease Type C (GlobeNewswire)
  • Cyclo goes forth with Niemann-Pick drugs approval bid despite Phase III miss (Clinical Trials Arena) +13.64%
  • Rafael Holdings Shares Fall 25% After Trappsol Cyclo Phase 3 Trial Misses Primary Endpoint (InvestorsHub) -34.98%
  • Rafael Holdings stock tumbles 25% as drug trial misses goal (Investing.com)
  • Rafael Holdings Announces Topline Results from the Pivotal Phase 3 TransportNPC Study of Trappsol Cyclo in Niemann-Pick Disease Type C (NPC) (GlobeNewswire)
  • Israel said to eye US listing for major defense firms (Investing.com)
  • Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results (GlobeNewswire) +19.10%
  • Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC Study Evaluating Trappsol Cyclo for the Treatment of Niemann-Pick Disease Type C (GlobeNewswire) -7.77%
  • Rafael Holdings Announces Patent Licensing Agreement with MIT for "Small Molecules to Improve Myelination in ApoE4 positive Alzheimer's Disease" (GlobeNewswire)
  • Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results (GlobeNewswire)
  • Rafael Holdings Reports First Quarter Fiscal 2026 Financial Results (GlobeNewswire)
  • Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-03-16---0.1250.21--
2026Q12025-12-11---0.1920.24--
2025Q42025-10-29---0.2810.35--
2025Q32025-06-11---0.1870.36--
2025Q22025-03-13---0.1900.08--
2025Q12024-12-11---0.3690.13--
2024Q42024-11-06---0.1840.17--
2024Q32024-06-14---1.3410.34--
2024Q22024-03-13--0.2440.07--
2024Q12023-12-14---0.1520.07--
2023Q42023-10-30--0.0520.07--
2023Q32023-06-13---0.0610.07--
2023Q22023-03-14---0.1380.07--
2023Q12022-12-13---0.2220.07--
2022Q42022-10-31---0.2390.07--
2022Q32022-06-14---0.2760.88--

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
No annual earnings.

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
No estimate revisions.

Estimate history

EPS, annual-0.917-0.349-0.651-1.465-6.217-0.367-1.429-1.037-0.577
Period201820192020202120222023202420252026
EPS, quarterly-0.184-0.369-0.19-0.187-0.281-0.192-0.125-0.083-0.178
PeriodQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26
Sales, annual4.3714.9314.910.8020.410.2790.6370.9170.874
Period201820192020202120222023202420252026
Sales, quarterly0.1650.1280.0770.3620.350.240.2110.1790.244
PeriodQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26
Shares, annual12.7314.12916.04317.97824.82624.62624.9651.57752.18
Period201820192020202120222023202420252026
Shares, quarterly24.9624.92525.2732.48751.57751.65552.00651.99452.18
PeriodQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26

Income statement, annual

Currency USD, millions
MetricTTM2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.870.870.920.640.280.410.804.914.93
Cost of Goods Sold Incl. D&A0.250.250.420.380.080.070.07--
Gross Profit0.630.630.490.260.200.340.73--
Selling, General and Administrative Excl. Other34.0234.0426.6013.0215.2460.8121.9311.519.75
Research and Development24.3324.3312.824.176.318.744.912.391.03
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-33.40-33.41-26.11-12.77-15.04-60.48-21.20-8.46-6.60
Interest Expense0.330.330.660.250.000.010.010.03-
Unusual Expense-3.920.008.9158.90-2.5879.642.97-1.59-0.81
Net Income Before Taxes-27.95-27.97-33.20-67.26-8.74-139.97-23.43-6.92-4.94
Income Taxes-0.00-0.01-2.55-2.68-0.260.000.020.03-0.02
Consolidated Net Income-27.95-27.95-30.64-65.00-8.69-140.55-23.06-10.75-4.92
Net Income From Continuing Operations-29.64-29.64-30.52-34.41-8.35-122.83-22.84-10.41-4.69
Net Income-29.64-29.64-30.52-34.41-8.66-124.66-24.54-10.41-4.69
EPS (Recurring)-0.63-0.58-0.830.28-0.44-3.44-1.34-0.72-0.39
EPS (Basic, Before Extraordinaries)-0.58-0.58-1.04-1.43-0.37-6.22-1.46-0.65-0.35
EPS (Diluted)-0.58-0.58-1.04-1.43-0.37-6.22-1.46-0.65-0.35
EBITDA-33.19-33.20-25.82-12.54-14.96-60.41-21.13-6.60-4.82
Non-Operating Income (Expense)1.855.782.484.653.720.160.75-0.010.85
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.221.101.681.811.735.2414.270.350.19
Price To Sales Ratio114.51114.0854.2255.54166.7697.391,042.6644.8555.73
Gross Margin71.8571.8553.9840.5072.0482.4491.27--
Operating Margin-3,821.17-3,822.54-2,847.22-2,004.08-5,391.76-14,750.49-2,643.27-172.40-133.77
Net Margin-3,390.73-3,390.73-3,328.24-5,401.88-3,103.94-30,404.39-3,060.35-212.12-95.17
Shares Outstanding52.1852.1851.5824.9624.6324.8317.9816.0414.13
Market Capitalization56.8856.8859.3037.1949.2542.55860.88224.11292.48

Income statement, quarterly

Currency USD, millions
Metric2026Q42026Q32026Q22026Q12025Q42025Q32025Q22025Q1
Total Revenue0.240.180.210.240.350.360.080.13
Cost of Goods Sold Incl. D&A0.060.060.070.060.070.100.130.12
Gross Profit0.180.120.140.180.280.26-0.050.01
Selling, General and Administrative Excl. Other9.916.996.8010.3213.046.173.543.85
Research and Development7.474.854.537.487.553.000.951.33
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-9.73-6.87-6.66-10.14-12.76-5.91-3.59-3.84
Interest Expense0.010.010.160.160.170.170.160.16
Unusual Expense0.00-3.72-0.200.000.001.011.955.95
Net Income Before Taxes-9.00-2.89-6.28-9.79-12.23-6.46-5.31-9.20
Income Taxes-0.070.010.050.01-0.17-2.410.020.01
Consolidated Net Income-8.93-2.90-6.33-9.80-12.05-4.05-5.33-9.21
Net Income From Continuing Operations-9.18-4.23-6.42-9.82-12.09-4.78-4.64-9.01
Net Income-9.18-4.23-6.42-9.82-12.09-4.78-4.64-9.01
EPS (Recurring)-0.18-0.13-0.13-0.19-0.28-0.16-0.13-0.20
EPS (Basic, Before Extraordinaries)-0.18-0.08-0.13-0.19-0.28-0.19-0.19-0.37
EPS (Diluted)-0.18-0.08-0.13-0.19-0.28-0.19-0.19-0.37
EBITDA-9.68-6.82-6.60-10.09-12.71-5.85-3.50-3.76
Non-Operating Income (Expense)0.740.260.340.510.700.630.400.76
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.180.140.310.600.720.280.400.28
Price To Sales Ratio114.5166.3951.0967.6579.2754.4870.4763.87
Gross Margin73.7768.7268.2575.4280.2971.82-66.233.91
Operating Margin-3,988.11-3,837.99-3,154.03-4,225.42-3,646.57-1,633.43-4,661.04-3,003.12
Net Margin-3,760.66-2,360.89-3,041.23-4,090.00-3,455.43-1,320.17-6,027.27-7,035.94
Shares Outstanding52.1851.9952.0151.6651.5832.4925.2724.92
Market Capitalization56.8866.0660.0447.7259.3051.3352.0646.11

Balance sheet, annual

Currency USD, millions
Metric2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments22.0752.7765.9479.5163.2312.856.2112.0240.50
Short Term Receivables0.441.836.132.520.300.830.400.763.67
Inventories0.380.280.000.000.000.000.000.000.00
Other Current Assets2.921.830.430.9144.811.073.230.470.33
Total Current Assets25.8256.7172.5082.94108.3514.769.8313.2644.51
Net Property, Plant & Equipment1.501.602.121.701.771.8444.4348.7350.11
Total Investments and Advances0.750.0014.5612.615.2485.4678.9277.1419.52
Long-Term Note Receivable2.041.861.15-1.579.071.501.401.00
Intangible Assets52.3852.516.471.57-1.571.571.571.65
Deferred Tax Assets-----0.000.010.020.00
Other Assets0.561.430.040.011.3942.910.080.010.13
Total Assets83.06114.1196.8398.83118.32154.06136.35142.14116.92
Short Term Debt Incl. Current Port. of LT Debt0.610.612.310.0015.0014.530.000.000.00
Accounts Payable7.016.892.560.330.561.160.920.800.37
Other Current Liabilities3.374.092.641.815.461.614.810.630.52
Total Current Liabilities10.9911.607.512.1521.0317.305.731.430.89
Long Term Debt0.000.080.000.000.000.000.0014.950.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.040.140.07------
Other Liabilities0.053.922.990.060.090.050.091.010.46
Total Liabilities11.0915.7410.572.2021.1117.355.8217.381.35
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity66.3194.3982.19100.29100.52122.29116.80110.98106.70
Total Shareholders Equity66.3194.3982.19100.29100.52122.29116.80110.98106.70
Accumulated Minority Interest5.663.984.07-3.66-3.3114.4213.7313.788.87
Total Equity71.9798.3786.2696.6397.21136.70130.53124.76115.56
Total Liabilities & Stockholders Equity83.06114.1196.8398.83118.32154.06136.35142.14116.92
Book Value Per Share1.271.833.294.074.056.807.287.858.38
Tangible Book Value Per Share0.270.813.034.014.056.807.187.748.25
Full-Time Employees172331142323195137
Price to Book Ratio0.860.680.450.490.436.791.922.641.09
Return on Assets-30.06-28.94-35.17-7.69-90.19-15.73-7.48-3.62-11.47
Return on Equity-36.88-34.57-37.71-8.32-110.26-19.11-9.14-4.31-14.61
Return on Invested Capital-44.69-32.31-41.87-8.63-124.02-20.07-8.92-3.73-10.92
Quick Ratio2.324.869.6538.675.150.851.729.2949.96
Current Ratio2.354.899.6538.675.150.851.729.2949.96

Cash flow, annual

Currency USD, millions
MetricTTM2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-27.95-27.95-30.64-65.00-2.21-142.38-24.77-10.75-4.92
Depreciation0.200.200.290.230.080.070.071.871.78
Other Funds (Non Cash)-3.15-3.1510.4657.59-8.66116.2410.083.06-1.61
Funds from Operations-30.99-30.99-19.90-7.19-10.79-26.07-14.61-5.82-4.78
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital0.990.990.97-0.61-0.09-0.01-0.991.151.64
Cash from Operating Activities-30.00-30.00-18.93-7.80-10.89-26.08-15.60-4.67-3.13
Capital Expenditures-0.00-0.00-0.02-0.180.00-0.000.00-0.53-0.40
Net Assets From Acquisitions0.000.00-2.710.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.080.080.012.350.000.004.610.004.59
Purchase or Sale of Investments0.000.0066.25-6.01-24.96-36.81-11.12-0.50-30.84
Purchase of Investments0.000.00-16.99-162.44-211.48-65.31-11.12-0.50-55.87
Sale Or Maturity of Investments0.000.0083.24156.44186.5228.500.000.0025.03
Other Uses-0.75-0.75-19.50-6.99-2.00-26.99-7.750.000.00
Other Sources0.000.000.000.0048.170.007.000.000.00
Cash from Investing Activities-0.68-0.6844.03-10.8221.21-63.80-7.26-1.03-26.65
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.000.0025.050.760.00103.9415.070.037.97
Repurchase of Common Pref Stock0.000.000.00-0.170.000.000.000.000.00
Sale of Common Pref Stock0.000.0025.050.930.00103.9415.070.037.97
Proceedsfrom Stock Options0.000.0025.050.930.00103.9413.000.007.78
Issuance or Reduction of Debt, Net-0.00-0.000.01-0.800.000.000.000.0018.34
Change in Long Term Debt-0.01-0.010.000.000.000.000.000.0018.34
Issuance of Long Term Debt0.000.000.000.000.000.000.000.0018.34
Reduction of Long Term Debt-0.01-0.010.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.10-0.10-0.21-0.14-15.22-0.0714.31-0.120.00
Other Financing Activities Uses-0.10-0.10-0.21-0.14-15.22-0.07-0.18-0.120.00
Cash from Financing Activities-0.11-0.1124.84-0.18-15.22103.8629.39-0.1026.30
Exchange Rate Effect0.080.080.15-0.02-0.15-0.310.12-0.02-0.30
Net Change in Cash-30.70-30.7050.09-18.82-5.0413.686.65-5.82-3.78
Free Cash Flow-30.00-30.00-18.93-7.95-10.89-26.08-15.81-5.20-3.53
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit--0.100.000.000.000.000.010.01-0.02

Balance sheet, quarterly

Currency USD, millions
Metric2026Q42026Q32026Q22026Q12025Q42025Q3
Cash & Short Term Investments22.0730.5037.7845.5452.7737.94
Short Term Receivables0.440.290.290.411.830.41
Inventories0.380.280.270.270.280.29
Other Current Assets2.923.794.102.101.833.81
Total Current Assets25.8234.8642.4548.3256.7142.44
Net Property, Plant & Equipment1.501.521.541.561.601.61
Total Investments and Advances0.750.750.750.500.000.00
Intangible Assets52.3852.4152.4452.4852.5160.88
Other Assets0.560.320.270.661.431.44
Total Assets83.0691.9999.31105.38114.11108.10
Short Term Debt Incl. Current Port. of LT Debt0.610.610.610.610.610.61
Accounts Payable7.017.048.176.796.897.79
Other Current Liabilities3.373.373.584.674.092.62
Total Current Liabilities10.9911.0212.3612.0811.6011.03
Long Term Debt0.000.000.050.060.080.08
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities0.040.140.140.140.149.00
Other Liabilities0.050.033.513.923.923.47
Total Liabilities11.0911.1916.0616.2015.7423.58
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity66.3175.3979.1785.1894.3980.58
Total Shareholders Equity66.3175.3979.1785.1894.3980.58
Accumulated Minority Interest5.665.424.094.003.983.94
Total Equity71.9780.8083.2689.1898.3784.52
Total Liabilities & Stockholders Equity83.0691.9999.31105.38114.11108.10
Book Value Per Share1.271.451.521.651.832.48
Tangible Book Value Per Share0.270.440.510.630.810.61
Full-Time Employees17---23-
Price to Book Ratio0.860.830.700.740.680.64
Return on Assets-30.06-32.54-36.31-32.43-28.94-21.83
Return on Equity-36.88-41.74-44.57-39.48-34.57-27.47
Return on Invested Capital-13.84-5.61-8.10-11.52-12.80-5.93
Quick Ratio2.323.143.413.984.863.82
Current Ratio2.353.163.444.004.893.85

Cash flow, quarterly

Currency USD, millions
Metric2026Q42026Q32026Q22026Q12025Q42025Q3
Net Income-8.93-2.90-6.33-9.80-12.05-4.05
Depreciation0.050.050.060.050.050.06
Other Funds (Non Cash)-0.29-3.550.190.510.741.33
Funds from Operations-9.27-6.40-6.09-9.24-11.26-2.66
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.89-0.90-1.432.420.88-0.54
Cash from Operating Activities-8.37-7.30-7.51-6.81-10.38-3.19
Capital Expenditures0.000.00-0.010.000.000.00
Net Assets From Acquisitions0.000.000.000.000.00-2.71
Sale of Fixed Assets and Businesses0.000.010.000.070.000.00
Purchase or Sale of Investments0.000.75-0.750.000.160.00
Purchase of Investments0.000.75-0.750.00-0.090.00
Sale Or Maturity of Investments0.000.000.000.000.260.00
Other Uses0.00-0.750.50-0.500.00-4.50
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.01-0.26-0.430.16-7.20
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.000.000.0025.000.04
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.000.000.0025.000.04
Proceedsfrom Stock Options0.000.000.000.0025.000.04
Issuance or Reduction of Debt, Net0.000.01-0.010.010.000.00
Change in Long Term Debt0.00-0.010.00-0.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.00-0.010.00-0.000.000.00
Net Financing Active Other Cash Flow-0.03-0.02-0.03-0.03-0.11-0.03
Other Financing Activities Uses-0.03-0.02-0.03-0.03-0.11-0.03
Cash from Financing Activities-0.03-0.01-0.04-0.0224.900.01
Exchange Rate Effect-0.030.020.050.040.150.00
Net Change in Cash-8.42-7.28-7.76-7.2314.83-10.38
Free Cash Flow-8.37-7.30-7.52-6.81-10.38-3.19

Revenue breakdown

Infusions Technology2025: 93.00K
Product2025: 515.00K 2026: 519.00K
Rental Related Party2025: 112.00K 2026: 119.00K
Rental Third Party2025: 197.00K 2026: 236.00K
United States2025: 917.00K 2026: 874.00K
Healthcare One2025: 515.00K 2026: 519.00K
Infusion Technology2025: 93.00K
Real Estate One2025: 309.00K 2026: 355.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.83%0.3M35.2M143.94K
2026-10-150.99%0.3M35.1M151.07K
2026-09-302.25%0.8M35.1M180.99K
2026-09-152.26%0.8M35.0M171.90K
2026-08-312.25%0.8M35.0M210.57K
2026-08-141.14%0.4M35.0M197.96K
2026-07-310.85%0.3M35.0M197.04K
2026-07-150.72%0.3M35.0M195.18K
2026-06-300.38%0.1M35.0M150.60K
2026-06-150.20%0.1M35.0M111.14K
2026-05-290.19%0.1M35.1M78.13K
2026-05-150.16%0.1M35.1M80.57K
2026-04-300.13%0.0M35.1M78.41K
2026-04-150.09%0.0M35.1M79.21K
2026-03-310.10%0.0M35.1M83.64K
2026-03-130.11%0.0M35.1M111.80K
2026-02-270.16%0.1M34.9M114.11K
2026-02-130.11%0.0M34.9M122.23K
2026-01-300.15%0.1M34.9M123.69K
2026-01-150.18%0.1M35.0M120.37K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.000.050.054.4261,0840.000.172-0.0110.000
call5.000.000.050.046.1964,2860.000.135-0.0130.000
call7.500.000.950.697.5965200.000.125-0.0160.000
put2.501.001.750.859.2862060.00-0.828-0.0110.000
put5.003.304.500.0015.7600.000.00-0.864-0.0140.000
put7.505.707.200.0021.0620.000.00-0.875-0.0150.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-098-KCurrent report2026-11-09SEC
2026-10-2910-KAnnual report pursuant to Section 13 or 15(d)2026-07-31SEC
2026-10-298-KCurrent report2026-10-29SEC
2026-10-274Statement of changes in beneficial ownership of securities2026-10-25SEC
2026-09-308-KCurrent report2026-09-30SEC
2026-09-234Statement of changes in beneficial ownership of securities2026-09-21SEC
2026-07-314Statement of changes in beneficial ownership of securities2026-07-29SEC
2026-07-088-KCurrent report2026-07-08SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-21SEC
2026-06-164Statement of changes in beneficial ownership of securities2026-06-13SEC
2026-06-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-04-30SEC
2026-06-118-KCurrent report2026-06-11SEC
2026-06-108-KCurrent report2026-06-10SEC
2026-04-228-KCurrent report2026-04-22SEC
2026-03-244Statement of changes in beneficial ownership of securities2026-03-21SEC
2026-03-174Statement of changes in beneficial ownership of securities2026-03-13SEC
2026-03-1610-QQuarterly report pursuant to Section 13 or 15(d)2026-01-31SEC
2026-03-168-KCurrent report2026-03-16SEC
2026-01-304Statement of changes in beneficial ownership of securities2026-01-28SEC
2026-01-294Statement of changes in beneficial ownership of securities2026-01-28SEC
2026-01-294Statement of changes in beneficial ownership of securities2026-01-28SEC
2026-01-294Statement of changes in beneficial ownership of securities2026-01-28SEC
2026-01-27S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-01-154Statement of changes in beneficial ownership of securities2026-01-13SEC
2026-01-154Statement of changes in beneficial ownership of securities2026-01-13SEC
2026-01-128-KCurrent report2026-01-08SEC
2025-12-234Statement of changes in beneficial ownership of securities2025-12-21SEC
2025-12-164Statement of changes in beneficial ownership of securities2025-12-13SEC
2025-12-1210-QQuarterly report pursuant to Section 13 or 15(d)2025-10-31SEC
2025-12-118-KCurrent report2025-12-11SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC2.63%
GEODE CAPITAL MANAGEMENT, LLC0.77%
BlackRock, Inc.0.75%
DIMENSIONAL FUND ADVISORS LP0.56%
VANGUARD FIDUCIARY TRUST CO0.40%
STATE STREET CORP0.30%
KAHN BROTHERS GROUP INC0.29%
IEQ CAPITAL, LLC0.28%
JANE STREET GROUP, LLC0.22%
WELLS FARGO & COMPANY/MN0.20%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND1.64%
VANGUARD EXTENDED MARKET INDEX FUND0.91%
Fidelity Extended Market Index Fund0.38%
iShares Micro-Cap ETF0.21%
U.S. MICRO CAP PORTFOLIO0.18%
Fidelity Total Market Index Fund0.14%
Fidelity Series Total Market Index Fund0.11%
Dimensional U.S. Small Cap ETF0.05%
U.S. VECTOR EQUITY PORTFOLIO0.04%
U.S. CORE EQUITY 2 PORTFOLIO0.04%

OakChart. RFL. Cached 15 minutes.

Some panels did not load: ratings, insider.